Oncology News | pharmaphorum

News

NICE backs first targeted therapy for ALK+ lung cancer

Roche's Alecensa has been recommended for routine NHS use as an adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first targeted therapy for this indication.

News

Head and neck cancer trials 'becoming less diverse'

Despite efforts in the US to increase the diversity of clinical trials, a study has found that in one form of cancer the trend seems to be going in the other direction.

News

Pfizer sticks $1.5bn on Triana's molecular glue tech

Big pharma's interest in using protein degradation as a therapeutic strategy continues with a wide-ranging deal between Pfizer and US biotech Triana Biomedicines that could be worth $1.5 bi

News

Transgene cervical cancer shot misses the mark in phase 2

Transgene's therapeutic vaccine for cervical and anogenital cancers has failed a phase 2 trial, but an efficacy signal warrants further study

News

Ono, Boehringer add to cancer pipelines with licensing deals

Ono Pharma and Boehringer Ingelheim both added to their cancer pipelines, licensing drugs from LigaChem Bio and Circle Pharma, respectively.

News

breast cancer awareness campaign - women in front of Westminster

UK celeb seeks funds to challenge NICE's Enhertu verdict

UK actor and TV personality Nadia Sawalha is spearheading a fundraising effort to launch an appeal against the recent rejection of a breast cancer therapy by cost-effectiveness agency NICE.

NICE backs first targeted therapy for ALK+ lung cancer

Head and neck cancer trials 'becoming less diverse'

Pfizer sticks $1.5bn on Triana's molecular glue tech

Transgene cervical cancer shot misses the mark in phase 2

Ono, Boehringer add to cancer pipelines with licensing deals

UK celeb seeks funds to challenge NICE's Enhertu verdict

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks